Contact: Merilee Raines, Chief Financial Officer, (207) 556-8155
FOR IMMEDIATE RELEASE
IDEXX Laboratories Announces Third Quarter Results and Two-for-One Stock Split
WESTBROOK, Maine, October 26, 2007— IDEXX Laboratories, Inc. (NASDAQ: IDXX), today reported that revenue for the third quarter of 2007 increased 22% to $229.4 million from $187.4 million for the third quarter of 2006. Earnings per diluted share (“EPS”) for the quarter ended September 30, 2007 were $0.81, compared to $0.76 for the same period in the prior year.
“In the third quarter we continued our sales momentum with strong revenue growth in the Companion Animal Group,” said Jonathan Ayers, Chairman and CEO. “Instrument sales and total instrument placements achieved record levels, which bodes well for the acceleration of instrument consumables sales in future periods. Our rapid assay and laboratory services lines of business also continued their revenue growth momentum in the third quarter, while digital radiography and computer systems logged double digit revenue growth. In this release we are providing initial revenue and earnings guidance for 2008, a year in which we will benefit from the launch of several new products, including three new instruments that will augment the IDEXX VetLab® suite of in-house analyzers.”
Companion Animal Group (“CAG”) revenue for the third quarter of 2007 increased 22% to $187.5 million from $153.1 million for the third quarter of 2006 due primarily to higher sales in all CAG product and service categories, with the largest growth in revenue dollars from laboratory and consulting services and from instruments and consumables products. Incremental sales from acquired businesses contributed 6% to revenue growth.
Water segment revenue for the third quarter of 2007 increased 5% to $17.4 million from $16.6 million for the third quarter of 2006 due primarily to higher worldwide sales volume, partly offset by lower average unit sales prices due to both higher relative sales in geographies where products are sold at lower average unit sales prices and greater price competition in certain geographies.
Production Animal Segment (“PAS”) revenue for the third quarter of 2007 increased 25% to $17.4 million from $13.9 million for the third quarter of 2006 due primarily to higher livestock diagnostics sales volume, including sales attributable to Institut Pourquier, which we acquired in March 2007. The favorable impact of higher sales volume was partly offset by lower average unit sales prices for products that test for transmissible spongiform encephalopathies (“TSE”) due to greater price competition.
IDEXX Announces Third Quarter Results
October 26, 2007
Page 2 of 13
The accompanying financial tables provide more information concerning our revenue and other operating results for the three and nine months ended September 30, 2007.
Year-to-Date Results
Year-to-date revenue increased 24% to $677.6 million from $546.9 million for the same period in 2006. Revenue for the nine months ended September 30, 2007, adjusted for the impacts of acquisitions and foreign currency exchange rates, increased 14%.
Year-to-date earnings per diluted share increased 1% to $2.12 from $2.09 for the same period in 2006. Non-GAAP adjusted diluted EPS for the nine months ended September 30, 2007 grew 16% to $2.37 from $2.05 for the same period in 2006. Non-GAAP adjusted diluted EPS for the nine months ended September 30, 2007 excludes the impact of acquisition-related purchase accounting and integration costs and the write-down of certain pharmaceutical assets in the second quarter. Non-GAAP adjusted diluted EPS for the nine months ended September 30, 2006 excludes the income tax benefits from certain discrete tax events. The accompanying financial table provides additional information and reconciles reported earnings per diluted share to these non-GAAP measures. Management believes adjusted diluted EPS is a useful non-GAAP financial measure to evaluate the results of ongoing operations, excluding significant specified items, period over period, and therefore believes that investors may find this information useful in addition to the GAAP results.
Additional Operating Results for the Third Quarter
Gross profit for the third quarter of 2007 increased $20.3 million, or 21%, to $118.5 million from $98.2 million for the third quarter of 2006. As a percentage of total revenue, gross profit was constant at 52%. The gross profit percentage was unfavorably impacted by greater relative sales of lower margin products and services such as laboratory and consulting services. Decreases in the gross margin percentage were offset by higher average selling prices, resulting in part from higher relative sales of combination rapid assay products such as the SNAP®4Dx®, which was launched in the U.S. in September 2006.
Research and development (“R&D”) expense for the third quarter of 2007 was $17.3 million, or 7.5% of revenue, compared to $13.7 million, or 7.3% of revenue, for the third quarter of 2006. R&D expense grew primarily as a result of increased product development spending related to IDEXX VetLab® instrumentation and to product development activities across all product and service categories.
Selling, general and administrative (“SG&A”) expense for the third quarter of 2007 was $65.1 million, or 28% of revenue, compared to $50.0 million, or 27% of revenue, for the third quarter of 2006. Increased SG&A expense was due primarily to higher personnel-related costs due, in part, to expanded worldwide sales, marketing and customer service headcount; higher spending on information technology, facilities and other general support functions; and incremental activities associated with recently acquired businesses.
IDEXX Announces Third Quarter Results
October 26, 2007
Page 3 of 13
IDEXX Laboratories Announces Two-for-One Stock Split
The Company also announced today that its Board of Directors approved a two-for-one split of its outstanding common stock. The stock split will be effected in the form of a 100% common stock dividend. Stockholders of record as of the close of business on November 5, 2007 will be issued one additional share for each share of common stock held on such date. The additional shares of common stock will be distributed on or about November 26, 2007. It is anticipated that the Company’s common stock will begin trading on a post-split basis on the business day following the distribution date. The stock split will double the number of outstanding common shares to approximately 61 million based on the number of shares outstanding as of October 22, 2007.
Outlook
The Company offers the following revised guidance for the full year of 2007:
| | · | Revenue is expected to be $910 to $915 million, updated from guidance of $900 to $905 million provided in July of this year, which represents revenue growth of 23% to 24% compared to 2006. |
| | · | Diluted earnings per share are expected to be $2.88 to $2.91 on a pre-split basis or $1.44 to $1.46 on a post-split basis. Excluding the impact of acquisition-related purchase accounting and integration costs and the write-down of certain pharmaceutical assets in the second quarter, non-GAAP adjusted diluted EPS are expected to be $3.13 to $3.16 on a pre-split basis or $1.56 to $1.58 on a post-split basis. Adjusted for discrete items in both 2006 and 2007, non-GAAP adjusted diluted EPS are projected to grow 17% to 18%. |
The Company offers the following guidance for the full year of 2008:
| | · | Revenue is expected to be $1.03 billion to $1.05 billion, which represents revenue growth of 13% to 15% compared to projected revenue for 2007 |
| | · | Diluted earnings per share are expected to be $3.63 to $3.73 on a pre-split basis or $1.82 to $1.87 on a post-split basis. Excluding the impact in 2007 of acquisition-related purchase accounting and integration costs and the write-down of certain pharmaceutical assets, non-GAAP adjusted diluted EPS are projected to grow 15% to 20%. |
Conference Call and Webcast Information
IDEXX Laboratories will be hosting a conference call today at 9:00 a.m. (eastern) to discuss its third quarter results. To participate in the conference call, dial 719-325-4744 or 877-681-3377 and reference confirmation code 2004728. An audio replay will be available through November 2, 2007 by dialing 719-457-0820 and referencing replay code 2004728.
The call will also be available via live or archived Webcast on the IDEXX Laboratories' web site at www.idexx.com.
IDEXX Announces Third Quarter Results
October 26, 2007
Page 4 of 13
About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice management systems and pharmaceuticals. IDEXX products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 4,500 people and offers products to customers in over 100 countries.
Note Regarding Forward-Looking Statements
This press release contains statements about the Company’s business prospects and estimates of the Company’s financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management’s expectations. Factors that could cause or contribute to such differences include the following: the Company’s ability to develop, manufacture, introduce and market new products and enhancements to existing products; the effectiveness of the Company’s sales and marketing activities; the Company’s ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; the impact of competition and technological change on the markets for the Company’s products; the effect of government regulation on the Company’s business, including government decisions about whether and when to approve the Company’s products and decisions regarding labeling, manufacturing and marketing products; the impact of distributor purchasing decisions on sales of the Company’s products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company’s products and services by veterinarians; the Company’s ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; disruptions, shortages or pricing changes that affect the Company’s purchases of products and materials from third parties, including from sole source suppliers; the effects of government regulatory decisions, customer demand, pricing and other factors on the realizability of the Company’s inventories; the Company’s ability to manufacture complex biologic products; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the loss of key employees. A further description of these and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, and quarterly report on Form 10-Q for the quarter ended June 30, 2007, in the section captioned "Risk Factors.”
IDEXX Announces Third Quarter Results
October 26, 2007
Page 5 of 13
IDEXX Laboratories, Inc. and Subsidiaries |
Consolidated Statement of Operations |
Amounts in thousands except per share data (Unaudited) |
| | | | Three Months Ended | | Nine Months Ended | |
| | | | September 30, | | September 30, | | September 30, | | September 30, | |
| | | | 2007 | | 2006 | | 2007 | | 2006 | |
Revenue: | Revenue | | $ | 229,385 | | $ | 187,380 | | $ | 677,586 | | $ | 546,908 | |
Expenses and | | | | | | | | | | | | | | |
Income: | Cost of revenue | | | 110,907 | | | 89,181 | | | 336,308 | | | 263,648 | |
| | Gross profit | | | 118,478 | | | 98,199 | | | 341,278 | | | 283,260 | |
| | Sales and marketing | | | 37,757 | | | 29,051 | | | 110,086 | | | 84,668 | |
| | General and administrative | | | 27,343 | | | 20,990 | | | 81,182 | | | 60,463 | |
| | Research and development | | | 17,281 | | | 13,696 | | | 50,569 | | | 39,666 | |
| | Income from operations | | | 36,097 | | | 34,462 | | | 99,441 | | | 98,463 | |
| | Interest income (expense), net | | | (515 | ) | | 609 | | | (1,321 | ) | | 1,972 | |
| | Income before provision for income taxes and partner's interest | | | 35,582 | | | 35,071 | | | 98,120 | | | 100,435 | |
| | Provision for income taxes | | | 9,787 | | | 10,118 | | | 29,634 | | | 31,581 | |
| | Partner's share of consolidated loss | | | - | | | - | | | - | | | (152 | ) |
Net Income: | Net income | | $ | 25,795 | | $ | 24,953 | | $ | 68,486 | | $ | 69,006 | |
| | Earnings per share: Basic | | $ | 0.84 | | $ | 0.80 | | $ | 2.22 | | $ | 2.19 | |
| | Earnings per share: Diluted | | $ | 0.81 | | $ | 0.76 | | $ | 2.12 | | $ | 2.09 | |
| | Shares outstanding: Basic | | | 30,547 | | | 31,210 | | | 30,843 | | | 31,491 | |
| | Shares outstanding: Diluted | | | 31,991 | | | 32,731 | | | 32,262 | | | 33,022 | |
IDEXX Laboratories, Inc. and Subsidiaries |
Key Operating Information (Unaudited) |
| | | | Three Months Ended | | Nine Months Ended | |
| | | | September 30, | | September 30, | | September 30, | | September 30, | |
| | | | 2007 | | 2006 | | 2007 | | 2006 | |
Key Operating | Gross profit | | | 51.7 | % | | 52.4 | % | | 50.4 | % | | 51.8 | % |
Ratios (as a | Sales, marketing, general and | | | | | | | | | | | | | |
percentage of | administrative expense | | | 28.5 | % | | 26.7 | % | | 28.2 | % | | 26.5 | % |
revenue): | Research and development expense | | | 7.5 | % | | 7.3 | % | | 7.5 | % | | 7.3 | % |
| | Income from operations | | | 15.7 | % | | 18.4 | % | | 14.7 | % | | 18.0 | % |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
International | International revenue (in thousands) | | $ | 89,547 | | $ | 63,955 | | $ | 264,514 | | $ | 190,355 | |
Revenue: | International revenue as percentage of | | | | | | | | | | | | | |
| | total revenue | | | 39.0 | % | | 34.1 | % | | 39.0 | % | | 34.8 | % |
IDEXX Announces Third Quarter Results
October 26, 2007
Page 6 of 13
|
Non-GAAP Financial Measures |
Amounts in thousands except per share data (Unaudited) |
| | | Three Months Ended | |
| | | | | Gross Profit | | Income from | | | | | | Earnings per Share | |
| | | Gross Profit | | as a % of Revenue | | Operations | | Net Income | | Diluted | |
| | | Sept. 30, | | Sept. 30, | | Sept. 30, | | Sept. 30, | | Sept. 30, | | Sept. 30, | | Sept. 30, | | Sept. 30, | | Sept. 30, | | Sept. 30, | |
| | | 2007 | | 2006 | | 2007 | | 2006 | | 2007 | | 2006 | | 2007 | | 2006 | | 2007 | | 2006 | |
| | | | | | | | | | | | | | | | | | | | | | |
| GAAP measurement | | $ | 118,478 | | $ | 98,199 | | | 51.7 | % | | 52.4 | % | $ | 36,097 | | $ | 34,462 | | $ | 25,795 | | $ | 24,953 | | $ | 0.81 | | $ | 0.76 | |
Acquisition-related purchase accounting & integration costs(1) | | | 87 | | | - | | | - | | | - | | | 139 | | | - | | | 90 | | | - | | | - | | | - | |
Non-GAAP comparative measurements(2) | | $ | 118,565 | | $ | 98,199 | | | 51.7 | % | | 52.4 | % | $ | 36,236 | | $ | 34,462 | | $ | 25,885 | | $ | 24,953 | | $ | 0.81 | | $ | 0.76 | |
| We use these supplemental non-GAAP financial measures to evaluate the Company's comparative financial performance. The specified items that are excluded in these non-GAAP measures are actual charges that impact net income and cash flows, however, we believe that it is useful to evaluate our core business performance period over period excluding these specified items, in addition to relying upon GAAP financial measures. |
| |
(1) We believe that the change from period to period due to specific acquisition-related purchase accounting and integration costs is not representative of ongoing operations and is not indicative of future performance. Specific acquisition-related discrete costs do not include amortization expense related to acquired intangible assets. We applied the statutory income tax rates of the applicable tax jurisdictions to calculate the after-tax impact of these discrete items. |
| |
(2) The sum of the individual items may not equal the non-GAAP measurement due to rounding of the individual items in this presentation. |
IDEXX Announces Third Quarter Results
October 26, 2007
Page 7 of 13
IDEXX Laboratories, Inc. and Subsidiaries |
Non-GAAP Financial Measures |
Amounts in thousands except per share data (Unaudited) |
| | | Nine Months Ended | |
| | | | | | | Gross Profit | | Income from | | | | | | Earnings per Share | |
| | | Gross Profit | | as a % of Revenue | | Operations | | Net Income | | Diluted | |
| | | Sept. 30, | | Sept. 30, | | Sept. 30, | | Sept. 30, | | Sept. 30, | | Sept. 30, | | Sept. 30, | | Sept. 30, | | Sept. 30, | | Sept. 30, | |
| | | 2007 | | 2006 | | 2007 | | 2006 | | 2007 | | 2006 | | 2007 | | 2006 | | 2007 | | 2006 | |
| | | | | | | | | | | | | | | | | | | | | | |
| GAAP measurement | | $ | 341,278 | | $ | 283,260 | | | 50.4 | % | | 51.8 | % | $ | 99,441 | | $ | 98,463 | | $ | 68,486 | | $ | 69,006 | | $ | 2.12 | | $ | 2.09 | |
| Specified items: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Write-downs of certain pharmaceutical assets(1) | | | 10,138 | | | - | | | 1.5 | % | | - | | | 10,138 | | | - | | | 6,392 | | | - | | | 0.20 | | | - | |
Acquisition-related purchase accounting & integration costs(2) | | | 1,979 | | | - | | | 0.3 | % | | - | | | 2,381 | | | - | | | 1,522 | | | - | | | 0.05 | | | - | |
Discrete income tax benefits(3) | | | - | | | - | | | - | | | - | | | - | | | - | | | - | | | (1,281 | ) | | - | | | (0.04 | ) |
Non-GAAP comparative measurements(4) | | $ | 353,395 | | $ | 283,260 | | | 52.2 | % | | 51.8 | % | $ | 111,960 | | $ | 98,463 | | $ | 76,400 | | $ | 67,725 | | $ | 2.37 | | $ | 2.05 | |
| We use these supplemental non-GAAP financial measures to evaluate the Company's comparative financial performance. The specified items that are excluded in these non-GAAP measures are actual charges that impact net income and cash flows, however, we believe that it is useful to evaluate our core business performance period over period excluding these specified items, in addition to relying upon GAAP financial measures. |
| |
(1) We believe that the write-down of certain pharmaceutical assets is not indicative of future performance because significant costs of a similar nature are not likely to recur within a reasonable period. We believe that we do not have other large inventory investments where the relationship of inventory to current sales volumes creates significant exposure to valuation risk. During the second quarter, we recognized a $9.1 million write-down of raw materials inventory and a $1.0 million write-off of a prepaid royalty license associated with Navigator® paste, a nitazoxanide product for the treatment of equine protozoal myeloencephalitis. We have written down these assets because product sales have been significantly lower than projected and we recently received notice from our third-party contract manufacturer of finished goods that the manufacturer will discontinue manufacturing the product in 2009. Due in part to an estimated production volume which is low, we believe that we will not be able to find an economically feasible replacement manufacturer and therefore that we will not be able to obtain the product after the termination of the existing manufacturing arrangement. We applied the statutory income tax rate of the applicable tax jurisdiction to calculate the after-tax impact of this discrete item. |
| |
(2) We believe that the change from period to period due to specific acquisition-related purchase accounting and integration costs is not representative of ongoing operations and is not indicative of future performance. Specific acquisition-related discrete costs do not include amortization expense related to acquired intangible assets. We applied the statutory income tax rates of the applicable tax jurisdictions to calculate the after-tax impact of these discrete items. |
| |
(3) We believe that certain significant discrete income tax items create impacts on financial measures that are not indicative of future performance because the items are not likely to recur within a reasonable period. For 2006, the separately identified discrete income tax benefits were composed of a tax benefit of $0.03 per diluted share due to a reduction of previously recorded international deferred tax liabilities as a result of obtaining certain multi-year tax incentives and a tax benefit of $0.01 per diluted share due to the release of a valuation allowance on international deferred tax assets as a result of a subsidiary demonstrating consistent sustained profitability. |
| |
(4) The sum of the individual items may not equal the non-GAAP measurement due to rounding of the individual items in this presentation. |
IDEXX Announces Third Quarter Results
October 26, 2007
Page 8 of 13
IDEXX Laboratories, Inc. and Subsidiaries |
Segment Information |
Amounts in thousands (Unaudited) |
| | | | Three Months Ended | | Nine Months Ended | |
| | | | September 30, | | September 30, | | September 30, | | September 30, | |
| | | | 2007 | | 2006 | | 2007 | | 2006 | |
Revenue: | Companion Animal Group | | $ | 187,481 | | $ | 153,058 | | $ | 554,939 | | $ | 449,324 | |
| | Water | | | 17,431 | | | 16,579 | | | 48,941 | | | 43,732 | |
| | Production Animal Segment | | | 17,377 | | | 13,907 | | | 52,871 | | | 42,310 | |
| | Other | | | 7,096 | | | 3,836 | | | 20,835 | | | 11,542 | |
| | Total | | $ | 229,385 | | $ | 187,380 | | $ | 677,586 | | $ | 546,908 | |
| | | | | | | | | | | | | | | |
Gross Profit: | Companion Animal Group | | $ | 93,949 | | $ | 76,739 | | $ | 269,328 | | $ | 223,475 | |
| | Water | | | 10,919 | | | 11,026 | | | 30,960 | | | 28,853 | |
| | Production Animal Segment | | | 10,412 | | | 9,481 | | | 32,677 | | | 27,634 | |
| | Other | | | 3,081 | | | 1,375 | | | 7,926 | | | 4,519 | |
| | Unallocated | | | 117 | | | (422 | ) | | 387 | | | (1,221 | ) |
| | Total | | $ | 118,478 | | $ | 98,199 | | $ | 341,278 | | $ | 283,260 | |
| | | | | | | | | | | | | | | |
Income from | | | | | | | | | | | | | | |
Operations: | Companion Animal Group | | $ | 28,529 | | $ | 26,436 | | $ | 75,293 | | $ | 78,541 | |
| | Water | | | 7,212 | | | 7,843 | | | 20,010 | | | 19,482 | |
| | Production Animal Segment | | | 2,561 | | | 3,908 | | | 10,286 | | | 11,279 | |
| | Other | | | 27 | | | 245 | | | (487 | ) | | 1,286 | |
| | Unallocated | | | (2,232 | ) | | (3,970 | ) | | (5,661 | ) | | (12,125 | ) |
| | Total | | $ | 36,097 | | $ | 34,462 | | $ | 99,441 | | $ | 98,463 | |
| | | | | | | | | | | | | | | |
Gross Profit | | | | | | | | | | | | | | |
(as a percentage | | | | | | | | | | | | | | |
of revenue): | Companion Animal Group | | | 50.1 | % | | 50.1 | % | | 48.5 | % | | 49.7 | % |
| | Water | | | 62.6 | % | | 66.5 | % | | 63.3 | % | | 66.0 | % |
| | Production Animal Segment | | | 59.9 | % | | 68.2 | % | | 61.8 | % | | 65.3 | % |
| | Other | | | 43.4 | % | | 35.9 | % | | 38.0 | % | | 39.2 | % |
| | | | | | | | | | | | | | | |
Income from | | | | | | | | | | | | | | |
Operations | | | | | | | | | | | | | | |
(as a percentage | | | | | | | | | | | | | | |
of revenue): | Companion Animal Group | | | 15.2 | % | | 17.3 | % | | 13.6 | % | | 17.5 | % |
| | Water | | | 41.4 | % | | 47.3 | % | | 40.9 | % | | 44.5 | % |
| | Production Animal Segment | | | 14.7 | % | | 28.1 | % | | 19.5 | % | | 26.7 | % |
| | Other | | | 0.4 | % | | 6.4 | % | | (2.3 | %) | | 11.1 | % |
IDEXX Announces Third Quarter Results
October 26, 2007
Page 9 of 13
IDEXX Laboratories, Inc. and Subsidiaries |
Revenues by Product and Service Categories |
Amounts in thousands (Unaudited) |
| |
Three Months Ended |
| | | Sept. 30, 2007 | | Sept. 30, 2006 | | Dollar Change | | Percentage Change | | Percentage Change from Currency (1) | | Percentage Change from Acquisitions (2) | | Percentage Change Net of Acquisitions and Currency Effect |
| | | | | | | | | | | | | | | | | | | | | | |
| CAG | | $ | 187,481 | | $ | 153,058 | | $ | 34,423 | | 22.5 | % | | 2.5 | % | | 5.9 | % | | 14.1 | % |
| Water | | | 17,431 | | | 16,579 | | | 852 | | 5.1 | % | | 3.0 | % | | - | | | 2.1 | % |
| PAS | | | 17,377 | | | 13,907 | | | 3,470 | | 25.0 | % | | 6.1 | % | | 12.8 | % | | 6.1 | % |
| Other | | | 7,096 | | | 3,836 | | | 3,260 | | 85.0 | % | | 2.8 | % | | 84.4 | % | | (2.2 | %) |
| Total | | $ | 229,385 | | $ | 187,380 | | $ | 42,005 | | 22.4 | % | | 2.8 | % | | 7.5 | % | | 12.1 | % |
Three Months Ended |
| | | Sept. 30,
2007 | | Sept. 30,
2006 | | Dollar Change | | Percentage Change | | Percentage Change from Currency (1) | | Percentage Change from Acquisitions (2) | | Percentage Change Net of Acquisitions and Currency Effect |
| | | | | | | | | | | | | | | | | | | | | | |
| Instruments and consumables | | $ | 71,443 | | $ | 60,295 | | $ | 11,148 | | 18.5 | % | | 3.3 | % | | - | | | 15.2 | % |
| Rapid assay products | | | 33,639 | | | 30,181 | | | 3,458 | | 11.5 | % | | 0.7 | % | | - | | | 10.8 | % |
| Laboratory and consulting services | | | 64,914 | | | 47,893 | | | 17,021 | | 35.5 | % | | 2.9 | % | | 18.9 | % | | 13.7 | % |
| Practice information management systems and digital radiography | | | 12,197 | | | 10,287 | | | 1,910 | | 18.6 | % | | 1.4 | % | | - | | | 17.2 | % |
| Pharmaceutical products | | | 5,288 | | | 4,402 | | | 886 | | 20.1 | % | | - | | | - | | | 20.1 | % |
| Net CAG revenue | | $ | 187,481 | | $ | 153,058 | | $ | 34,423 | | 22.5 | % | | 2.5 | % | | 5.9 | % | | 14.1 | % |
(1) Represents the percentage change in revenue attributed to the effect of changes in currency rates from the three months ended September 30, 2006 to the three months ended September 30, 2007.
(2) Represents the percentage change in revenue attributed to incremental revenues during the three months ended September 30, 2007 compared to the three months ended September 30, 2006 from businesses acquired since July 1, 2006.
IDEXX Announces Third Quarter Results
October 26, 2007
Page 10 of 13
IDEXX Laboratories, Inc. and Subsidiaries |
Revenues by Product and Service Categories |
Amounts in thousands (Unaudited) |
Nine Months Ended |
| | | Sept. 30, 2007 | | Sept. 30, 2006 | | Dollar Change | | Percentage Change | | Percentage Change from Currency (1) | | Percentage Change from Acquisitions (2) | | Percentage Change Net of Acquisitions and Currency Effect |
| | | | | | | | | | | | | | | | | | | | | | |
| CAG | | $ | 554,939 | | $ | 449,324 | | $ | 105,615 | | 23.5 | % | | 2.2 | % | | 6.3 | % | | 15.0 | % |
| Water | | | 48,941 | | | 43,732 | | | 5,209 | | 11.9 | % | | 3.0 | % | | - | | | 8.9 | % |
| PAS | | | 52,871 | | | 42,310 | | | 10,561 | | 25.0 | % | | 6.4 | % | | 10.4 | % | | 8.2 | % |
| Other | | | 20,835 | | | 11,542 | | | 9,293 | | 80.5 | % | | 2.7 | % | | 77.7 | % | | 0.1 | % |
| Total | | $ | 677,586 | | $ | 546,908 | | $ | 130,678 | | 23.9 | % | | 2.6 | % | | 7.6 | % | | 13.7 | % |
Nine Months Ended |
| | | Sept. 30, 2007 | | Sept. 30, 2006 | | Dollar Change | | Percentage Change | | Percentage Change from Currency (1) | | Percentage Change from Acquisitions (2) | | Percentage Change Net of Acquisitions and Currency Effect |
| | | | | | | | | | | | | | | | | | | | | | |
| Instruments and consumables | | $ | 209,889 | | $ | 177,326 | | $ | 32,563 | | 18.4 | % | | 2.8 | % | | - | | | 15.6 | % |
| Rapid assay products | | | 101,464 | | | 88,812 | | | 12,652 | | 14.2 | % | | 0.5 | % | | 1.9 | % | | 11.8 | % |
| Laboratory and consulting services | | | 191,350 | | | 139,287 | | | 52,063 | | 37.4 | % | | 3.1 | % | | 19.1 | % | | 15.2 | % |
| Practice information management systems and digital radiography | | | 36,419 | | | 30,764 | | | 5,655 | | 18.4 | % | | 0.8 | % | | - | | | 17.6 | % |
| Pharmaceutical products | | | 15,817 | | | 13,135 | | | 2,682 | | 20.4 | % | | - | | | - | | | 20.4 | % |
| Net CAG revenue | | $ | 554,939 | | $ | 449,324 | | $ | 105,615 | | 23.5 | % | | 2.2 | % | | 6.3 | % | | 15.0 | % |
(1) Represents the percentage change in revenue attributed to the effect of changes in currency rates from the nine months ended September 30, 2006 to the nine months ended September 30, 2007.
(2) Represents the percentage change in revenue attributed to incremental revenues during the nine months ended September 30, 2007 compared to the nine months ended September 30, 2006 from businesses acquired since January 1, 2006.
IDEXX Announces Third Quarter Results
October 26, 2007
Page 11 of 13
IDEXX Laboratories, Inc. and Subsidiaries |
Consolidated Balance Sheet |
Amounts in thousands (Unaudited) |
| | | | September 30, | | December 31, | |
| | | | 2007 | | 2006 | |
Assets: | Current Assets: | | | | | | | |
| | Cash and cash equivalents | | $ | 58,507 | | $ | 61,666 | |
| | Short-term investments | | | - | | | 35,000 | |
| | Accounts receivable, net | | | 103,407 | | | 81,389 | |
| | Inventories | | | 96,273 | | | 95,996 | |
| | Other current assets | | | 35,562 | | | 28,212 | |
| | Total current assets | | | 293,749 | | | 302,263 | |
| | Property and equipment, at cost | | | 233,219 | | | 191,538 | |
| | Less: accumulated depreciation | | | 106,354 | | | 91,910 | |
| | Property and equipment, net | | | 126,865 | | | 99,628 | |
| | Other long-term assets, net | | | 253,619 | | | 157,669 | |
| | Total assets | | $ | 674,233 | | $ | 559,560 | |
Liabilities and | | | | | | | | |
Stockholders’ | | | | | | | | |
Equity: | Current Liabilities: | | | | | | | |
| | Accounts payable | | $ | 21,786 | | $ | 24,374 | |
| | Accrued expenses | | | 99,350 | | | 90,715 | |
| | Debt | | | 77,990 | | | 678 | |
| | Deferred revenue | | | 10,044 | | | 8,976 | |
| | Total current liabilities | | | 209,170 | | | 124,743 | |
| | Long-term debt, net of current portion | | | 5,911 | | | 6,447 | |
| | Other long-term liabilities | | | 39,012 | | | 18,509 | |
| | Total long-term liabilities | | | 44,923 | | | 24,956 | |
| | | | | | | | | |
| | Stockholders’ Equity: | | | | | | | |
| | Common stock | | | 4,716 | | | 4,662 | |
| | Additional paid-in capital | | | 512,266 | | | 479,993 | |
| | Deferred stock units | | | 2,147 | | | 1,852 | |
| | Retained earnings | | | 560,334 | | | 490,614 | |
| | Treasury stock, at cost | | | (677,509 | ) | | (577,826 | ) |
| | Accumulated other comprehensive income | | | 18,186 | | | 10,566 | |
| | Total stockholders’ equity | | | 420,140 | | | 409,861 | |
| | Total liabilities and stockholders’ equity | | $ | 674,233 | | $ | 559,560 | |
IDEXX Laboratories, Inc. and Subsidiaries |
Key Balance Sheet Information (Unaudited) |
| | | | September 30, | | December 31, | |
| | | | 2007 | | 2006 | |
| | | | | | | |
Key | Total cash, cash equivalents and investments (in thousands) | | $ | 58,507 | | $ | 96,666 | |
Balance Sheet | Days sales outstanding | | | 42 | | | 38 | |
Information: | Inventory turns | | | 2.1 | | | 1.9 | |
IDEXX Announces Third Quarter Results
October 26, 2007
Page 12 of 13
IDEXX Laboratories, Inc. and Subsidiaries |
Consolidated Statement of Cash Flows |
Amounts in thousands (Unaudited) |
| | | | Nine Months Ended | |
| | | | September 30, | | September 30, | |
| | | | 2007 | | 2006 | |
Operating: | Cash Flows from Operating Activities: | | | | | |
| | Net income | | $ | 68,486 | | $ | 69,006 | |
| | Non-cash charges | | | 30,907 | | | 17,484 | |
| | Changes in current assets and liabilities, net of | | | | | | | |
| | acquisitions and disposals | | | (4,200 | ) | | (15,078 | ) |
| | Net cash provided by operating activities | | $ | 95,193 | | $ | 71,412 | |
Investing: | Cash Flows from Investing Activities: | | | | | | | |
| | Decrease in investments, net | | | 35,000 | | | 22,014 | |
| | Purchase of property and equipment | | | (41,723 | ) | | (21,476 | ) |
| | Purchase of land and buildings | | | - | | | (11,521 | ) |
| | Acquisition of businesses and intangible assets | | | (87,738 | ) | | (9,367 | ) |
| | Acquisition of equipment leased to customers | | | (740 | ) | | (1,370 | ) |
| | Net cash provided (used) by investing activities | | $ | (95,201 | ) | $ | (21,720 | ) |
Financing: | Cash Flows from Financing Activities: | | | | | | | |
| | Borrowings (payments) of notes payable, net | | | 68,819 | | | (712 | ) |
| | Purchase of treasury stock | | | (99,684 | ) | | (93,832 | ) |
| | Proceeds from the exercise of stock options | | | 17,655 | | | 18,843 | |
| | Tax benefit from exercise of stock options | | | 7,544 | | | 8,747 | |
| | Net cash provided (used) by financing activities | | $ | (5,666 | ) | $ | (66,954 | ) |
| | Net effect of exchange rate changes | | | 2,515 | | | 1,061 | |
| | Net decrease in cash and cash equivalents | | | (3,159 | ) | | (16,201 | ) |
| | Cash and cash equivalents, beginning of period | | | 61,666 | | | 67,151 | |
| | Cash and cash equivalents, end of period | | $ | 58,507 | | $ | 50,950 | |
IDEXX Laboratories, Inc. and Subsidiaries |
Free Cash Flow |
Amounts in thousands (Unaudited) |
| | | | Nine Months Ended | |
| | | | September 30, | | September 30, | |
| | | | 2007 | | 2006 | |
Free Cash | | | | | | |
Flow: | Net cash provided by operating activities | | $ | 95,193 | | $ | 71,412 | |
| | Financing cash flows attributable to tax benefits from exercise of stock options | | | 7,544 | | | 8,747 | |
| | Purchase of fixed assets | | | (41,723 | ) | | (32,997 | ) |
| | Acquisition of equipment leased to customers | | | (740 | ) | | (1,370 | ) |
| Free cash flow | | $ | 60,274 | | $ | 45,792 | |
| | Free cash flow indicates the cash generated from operations and tax benefits attributable to stock option exercises, reduced by investments in fixed assets. We feel free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in fixed assets that are required to operate the business. We believe this is a common financial measure useful to further evaluate the results of operations. |
IDEXX Announces Third Quarter Results
October 26, 2007
Page 13 of 13
IDEXX Laboratories, Inc. and Subsidiaries |
Common Stock Repurchases |
Amounts in thousands except per share data (Unaudited) |
| | | Three Months Ended | | Nine Months Ended | |
| | | September 30, | | September 30, | | September 30, | | September 30, | |
| | | 2007 | | 2006 | | 2007 | | 2006 | |
| Share repurchases during the period | | | 70 | | | 116 | | | 1,129 | | | 1,195 | |
| Average price paid per share | | $ | 101.83 | | $ | 74.50 | | $ | 87.86 | | $ | 78.53 | |
| | | | | | | | | | | | | | |
| Shares remaining under repurchase authorization as of September 30, 2007 | | 1,585 | | | | |
IDEXX Laboratories, Inc. and Subsidiaries |
Pro Forma Earnings per Share Adjusted for Stock Split (Unaudited) |
| | | Three Months Ended | | Nine Months Ended | |
| | | September 30, | | September 30, | | September 30, | | September 30, | |
| Basic | | 2007 | | 2006 | | 2007 | | 2006 | |
| As reported | | $ | 0.84 | | $ | 0.80 | | $ | 2.22 | | $ | 2.19 | |
| Pro forma | | $ | 0.42 | | $ | 0.40 | | $ | 1.11 | | $ | 1.10 | |
| Diluted | | | | | | | | | | | | | |
| As reported | | $ | 0.81 | | $ | 0.76 | | $ | 2.12 | | $ | 2.09 | |
| Pro forma | | $ | 0.40 | | $ | 0.38 | | $ | 1.06 | | $ | 1.04 | |
